Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts

Arthritis and Rheumatism

Volumn 64, Issue 6, 2012, Pages 1978-1989

  Tsou, Pei Suen ^a   Talia, Nadine N ^a   Pinney, Adam J ^a   Kendzicky, Ann ^a   Piera Velazquez, Sonsoles ^b   Jimenez, Sergio A ^b   Seibold, James R ^c   Phillips, Kristine ^a   Koch, Alisa E ^a,d,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Scleroderma Research Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; COLLAGEN TYPE 1; CYSTEINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE PHOSPHATASE 1B; REACTIVE OXYGEN METABOLITE; THIOL;

ADULT; ARTICLE; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; OXIDATION KINETICS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS;

ACETYLCYSTEINE; CELLS, CULTURED; COLLAGEN TYPE I; FIBROBLASTS; FREE RADICAL SCAVENGERS; HUMANS; OXIDATIVE STRESS; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; REACTIVE OXYGEN SPECIES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SCLERODERMA, SYSTEMIC; SKIN; SUPEROXIDES;

EID: 84861837654     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34336     Document Type: Article

References (48)

1. LeRoy EC,. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54: 880-9.
2. Jelaska A, Korn JH,. Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000; 43: 2230-9.
3. Pandolfi A, Florita M, Altomare G, Pigatto P, Donati MB, Poggi A,. Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis. Proc Soc Exp Biol Med 1989; 191: 1-4.
4. Gay S, Jones RE Jr, Huang GQ, Gay RE,. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989; 92: 301-3.
5. Klareskog L, Gustafsson R, Scheynius A, Hallgren R,. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990; 33: 1534-41.
6. Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M,. Selective upregulation of platelet-derived growth factor α receptors by transforming growth factor β in scleroderma fibroblasts. J Exp Med 1992; 175: 1227-34.
7. Kawaguchi Y, Hara M, Wright TM,. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103: 1253-60.
8. Svegliati S, Cancello R, Sambo P, Luchetti M, Paroncini P, Orlandini G, et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2: amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005; 280: 36474-82.
9. Li JM, Shah AM,. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 2004; 287: R1014-30.
10. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM,. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995; 38: 1060-7.
11. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001; 44: 2653-64.
12. Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S, et al. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999; 112: 78-84.
13. Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology (Oxford) 2006; 45: 815-8.
14. Servettaz A, Guilpain P, Goulvestre C, Chereau C, Hercend C, Nicco C, et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 2007; 66: 1202-9.
15. Blake DR, Winyard P, Scott DG, Brailsford S, Blann A, Lunec J,. Endothelial cell cytotoxicity in inflammatory vascular diseases-the possible role of oxidised lipoproteins. Ann Rheum Dis 1985; 44: 176-82.
16. Murrell GA, Francis MJ, Bromley L,. Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 1990; 265: 659-65.
17. King MR, Ismail AS, Davis LS, Karp DR,. Oxidative stress promotes polarization of human T cell differentiation toward a T helper 2 phenotype. J Immunol 2006; 176: 2765-72.
18. Finch WR, Rodnan GP, Buckingham RB, Prince RK, Winkelstein A,. Bleomycin-induced scleroderma. J Rheumatol 1980; 7: 651-9.
19. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I. local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 456-62.
20. Servettaz A, Goulvestre C, Kavian N, Nicco C, Guilpain P, Chereau C, et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 2009; 182: 5855-64.
21. Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001; 28: 2257-62.
22. Failli P, Palmieri L, D'Alfonso C, Giovannelli L, Generini S, Rosso AD, et al. Effect of N-acetyl-L-cysteine on peroxynitrite and superoxide anion production of lung alveolar macrophages in systemic sclerosis. Nitric Oxide 2002; 7: 277-82.
23. Rosato E, Borghese F, Pisarri S, Salsano F,. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol 2009; 28: 1379-84.
24. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-42.
25. Aruoma OI, Halliwell B, Hoey BM, Butler J,. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6: 593-7.
26. Ceconi C, Curello S, Cargnoni A, Ferrari R, Albertini A, Visioli O,. The role of glutathione status in the protection against ischaemic and reperfusion damage: effects of N-acetyl cysteine. J Mol Cell Cardiol 1988; 20: 5-13.
27. Fung HL, Chong S, Kowaluk E, Hough K, Kakemi M,. Mechanisms for the pharmacologic interaction of organic nitrates with thiols: existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N-acetylcysteine. J Pharmacol Exp Ther 1988; 245: 524-30.
28. Denu JM, Tanner KG,. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 1998; 37: 5633-42.
29. Meng TC, Fukada T, Tonks NK,. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002; 9: 387-99.
30. Klinghoffer RA, Kazlauskas A,. Identification of a putative Syp substrate, the PDGF β receptor. J Biol Chem 1995; 270: 22208-17.
31. Liu F, Chernoff J,. Protein tyrosine phosphatase 1B interacts with and is tyrosine phosphorylated by the epidermal growth factor receptor. Biochem J 1997; 327: 139-45.
32. Louneva N, Huaman G, Fertala J, Jimenez SA,. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum 2006; 54: 1298-308.
33. Allanore Y, Borderie D, Perianin A, Lemarechal H, Ekindjian OG, Kahan A,. Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arthritis Res Ther 2005; 7: R93-100.
34. Firuzi O, Fuksa L, Spadaro C, Bousova I, Riccieri V, Spadaro A, et al. Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol 2006; 58: 951-7.
35. Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A,. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 2004; 116: 595-600.
36. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60: 219-24.
37. Samuel G, Bujor A, Nakerakanti S, Hant F, Trojanowska M,. Autocrine transforming growth factor β signaling regulates extracellular signal-regulated kinase 1/2 phosphorylation via modulation of protein phosphatase 2A expression in scleroderma fibroblasts. Fibrogenesis Tissue Repair 2010; 3: 25.
38. Haj FG, Markova B, Klaman LD, Bohmer FD, Neel BG,. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J Biol Chem 2003; 278: 739-44.
39. Byon JC, Kusari AB, Kusari J,. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol Cell Biochem 1998; 182: 101-8.
40. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, Haj F, Wang Y, Minokoshi Y, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002; 2: 489-95.
41. Flint AJ, Tiganis T, Barford D, Tonks NK,. Development of "substrate-trapping" mutants to identify physiological substrates of protein tyrosine phosphatases. Proc Natl Acad Sci U S A 1997; 94: 1680-5.
42. Aoki N, Matsuda T,. A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem 2000; 275: 39718-26.
43. Chiarugi P, Cirri P,. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci 2003; 28: 509-14.
44. Lou YW, Chen YY, Hsu SF, Chen RK, Lee CL, Khoo KH, et al. Redox regulation of the protein tyrosine phosphatase PTP1B in cancer cells. FEBS J 2008; 275: 69-88.
45. Sfrent-Cornateanu R, Mihai C, Stoian I, Lixandru D, Bara C, Moldoveanu E,. Antioxidant defense capacity in scleroderma patients. Clin Chem Lab Med 2008; 46: 836-41.
46. Ammendola R, Ruocchio MR, Chirico G, Russo L, De Felice C, Esposito F, et al. Inhibition of NADH/NADPH oxidase affects signal transduction by growth factor receptors in normal fibroblasts. Arch Biochem Biophys 2002; 397: 253-7.
47. Kappert K, Sparwel J, Sandin A, Seiler A, Siebolts U, Leppanen O, et al. Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in cultured VSMCs and in restenosis. Arterioscler Thromb Vasc Biol 2006; 26: 2644-51.
48. Kovalenko M, Denner K, Sandstrom J, Persson C, Gross S, Jandt E, et al. Site-selective dephosphorylation of the platelet-derived growth factor β-receptor by the receptor-like protein-tyrosine phosphatase DEP-1. J Biol Chem 2000; 275: 16219-26.